Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UBR1
UPID:
BUP1_HUMAN
Alternative names:
BUP-1; Beta-alanine synthase; N-carbamoyl-beta-alanine amidohydrolase
Alternative UPACC:
Q9UBR1; A3KMF8; Q9UIR3
Background:
Beta-ureidopropionase, also known as BUP-1, Beta-alanine synthase, and N-carbamoyl-beta-alanine amidohydrolase, plays a crucial role in pyrimidine degradation. It catalyzes the conversion of N-carbamoyl-beta-alanine and N-carbamoyl-beta-aminoisobutyrate into their respective products, facilitating the removal of nitrogen waste from the body.
Therapeutic significance:
Beta-ureidopropionase deficiency, a rare metabolic disorder, is characterized by muscular hypotonia, dystonic movements, and severe developmental delay. This condition underscores the enzyme's vital role in metabolic pathways, suggesting that targeted therapies could mitigate its debilitating effects.